Loss of the Y chromosome is transcriptionally silent in clear cell renal cell carcinoma and across cancer entities
- 1Department of Internal Medicine I, Hematology, Oncology and Stem Cell Transplantation, Faculty of Medicine, Medical Center - University of Freiburg, Freiburg, G
Abstract
Tumors in men often lose the Y chromosome. In some tumor types, this is predictive of poor outcome. Given the male predominance and high LOY frequency in clear cell renal cell carcinoma (ccRCC), we asked whether LOY might impact the transcriptome of ccRCC. We determined somatic Y chromosome status and performed differential expression analysis on tumor RNA-sequencing samples of two human ccRCC cohorts (TCGA-KIRC, CPTAC-ccRCC) and in an autochthonous murine ccRCC model with renal epithelium-specific deletion of Vhl, Trp53 and Rb1. We additionally derived five isogenic Y-deficient and five Y chromosome-retaining clones of the human ccRCC cell line 786-O. Across all three settings, transcriptional changes were largely restricted to the expected gene dosage effects of male-specific Y (MSY) and pseudoautosomal region (PAR) genes, without large effects on autosomal genes. At the pathway level, we identified a modest but reproducible response in the human cohorts, converging on cell cycle, ribosomal biogenesis and DNA repair genes. A pan-cancer meta-analysis across TCGA entities recovered the same pattern, with no autosomal gene showing a large consistent effect. In some entities, but not in ccRCC, cancer/testis antigen expression was higher in LOY tumors. We conclude that, apart from direct gene dosage, modest pathway-level shifts and altered silencing of cancer/testis antigens, LOY is transcriptionally silent in adult humans and mice. Y-chromosomal genes are therefore unlikely to act as transcriptional drivers of ccRCC and other cancer entities.
Related
- Distribution of Pathological Entities and Surgical Procedures Across Cervical Levels in Degenerative Cervical Myelopathy: An Exploratory Single-Center Analysis
- Silent Invasion: Isolated Right Ventricular Metastasis from Hepatocellular Carcinoma Diagnosed by Transvenous Biopsy.
- Silent scars: psychopathology networks across cumulative childhood trauma exposure and the role of shame about eating
- Taming Mre11-Rad50 at Telomeres: Convergent Strategies for Chromosome-End Protection Across Evolution.
- Resource limitation rewires chromosome instability and ploidy evolution across in vitro and in vivo cancer models
BibTeX
@misc{waterhoelter2026loss,
title = {{Loss of the Y chromosome is transcriptionally silent in clear cell renal cell carcinoma and across cancer entities}},
author = {A. Waterhoelter and R. Scholz and A. Tsouris and F. Cuomo and M. Adlesic and L. Nguekeu Zebaze and C. Witt and Z. Rodriguez Hernandez and A. Koettgen and M. Boerries and P. Schlosser and I. J. Frew},
howpublished = {bioRxiv},
year = {2026},
month = oct,
doi = {10.64898/2026.10.08.757570},
url = {https://www.biorxiv.org/content/10.64898/2026.10.08.757570v1},
note = {CC BY},
}
RIS
TY - UNPB
TI - Loss of the Y chromosome is transcriptionally silent in clear cell renal cell carcinoma and across cancer entities
AU - A. Waterhoelter
AU - R. Scholz
AU - A. Tsouris
AU - F. Cuomo
AU - M. Adlesic
AU - L. Nguekeu Zebaze
AU - C. Witt
AU - Z. Rodriguez Hernandez
AU - A. Koettgen
AU - M. Boerries
AU - P. Schlosser
AU - I. J. Frew
PY - 2026
DA - 2026/10/08
PB - bioRxiv
DO - 10.64898/2026.10.08.757570
UR - https://www.biorxiv.org/content/10.64898/2026.10.08.757570v1
AB - Tumors in men often lose the Y chromosome. In some tumor types, this is predictive of poor outcome. Given the male predominance and high LOY frequency in clear cell renal cell carcinoma (ccRCC), we asked whether LOY might impact the transcriptome of ccRCC. We determined somatic Y chromosome status and performed differential expression analysis on tumor RNA-sequencing samples of two human ccRCC cohorts (TCGA-KIRC, CPTAC-ccRCC) and in an autochthonous murine ccRCC model with renal epithelium-specific deletion of Vhl, Trp53 and Rb1. We additionally derived five isogenic Y-deficient and five Y chromosome-retaining clones of the human ccRCC cell line 786-O. Across all three settings, transcriptional changes were largely restricted to the expected gene dosage effects of male-specific Y (MSY) and pseudoautosomal region (PAR) genes, without large effects on autosomal genes. At the pathway level, we identified a modest but reproducible response in the human cohorts, converging on cell cycle, ribosomal biogenesis and DNA repair genes. A pan-cancer meta-analysis across TCGA entities recovered the same pattern, with no autosomal gene showing a large consistent effect. In some entities, but not in ccRCC, cancer/testis antigen expression was higher in LOY tumors. We conclude that, apart from direct gene dosage, modest pathway-level shifts and altered silencing of cancer/testis antigens, LOY is transcriptionally silent in adult humans and mice. Y-chromosomal genes are therefore unlikely to act as transcriptional drivers of ccRCC and other cancer entities.
ER -